Article Text

OP0055 Anti-RNA Polymerase III Antibodies in Patients with Systemic Sclerosis: A Eustar Multicenter Collaborative Study
  1. M.G. Lazzaroni1,
  2. E. Colombo1,
  3. I. Cavazzana2,
  4. O. Distler3,
  5. R. Hesselstrand4,
  6. V. Smith5,
  7. P. Caramaschi6,
  8. E. Hachulla7,
  9. A. Balbir-Gurman8,
  10. K. Romanowska-Pròchnicka9,10,
  11. V. Riccieri11,
  12. Y. Allanore12,
  13. P. Airo'2
  14. on behalf of EUSTAR co-authors
  1. 1Rheumatology and Clinical Immunology Unit, University and Spedali Civili of Brescia
  2. 2Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, Brescia, Italy
  3. 3Division of Rheumatology, University Hospital, Zurich, Switzerland
  4. 4Department of Rheumatology, Lund University, Lund, Sweden
  5. 5Department of Rheumatology, University Hospital and Gent University, Gent, Belgium
  6. 6Rheumatology Unit, Department of Medicine, Azienda Ospedaliera Universitaria, Verona, Italy
  7. 7Department of Internal Medicine, University Lille Nord-de-France, Lille, France
  8. 8B.Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel
  9. 9Department of Pathophysiology, Medical University of Warsaw
  10. 10Department of Connective Tissue Diseases, Institute of Rheumatology, Warsaw, Poland
  11. 11Department of Internal Medicine, Sapienza University of Rome, Rome, Italy
  12. 12Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris, France


Background Most data on the clinical associations of anti-RNA polymerase III (RNAP) antibodies in patients with Systemic Sclerosis (SSc) derive from single-center studies or relatively small positive case number reports.

Objectives To analyse the clinical associations of anti-RNAP in a large cohort of patients with different geographic and ethnic origin using the multicenter EUSTAR database.

Methods Patients from the EUSTAR database were included when the item anti-RNAP was fulfilled in at least one visit, and considered anti-RNAP+ when scored positive in at least one determination. In a second phase, EUSTAR centers were asked to participate to a case-control study, fulfilling a supplementary form dedicated to skin involvement progression, gastric antral vascular ectasia (GAVE), and malignancies. Malignancies diagnosed between 6 months before and 12 months after the onset of SSc were defined as “synchronous to the onset of SSc”. Centers were asked to match anti-RNAP+ cases with anti-RNAP- SSc controls, paired for sex, cutaneous subset, and disease duration. Univariate methods were used to compare patients with and without anti-RNAP.

Results Among 11,399 SSc patients registered in the EUSTAR database, 4,986 had anti-RNAP antibodies status available including 223 anti-RNAP+ (4.5%) and 4,763 anti-RNAP-. The differences between the two groups are shown in Figure 1. There was no difference as far as ethnicity (Caucasians: 94.2% vs 95.0%), age at disease onset, disease duration, length of follow-up, and other parameters included in the database. Ten centers participated in the case-control study, collecting 126 anti-RNAP+ cases (23% male, 59% with diffuse cutaneous involvement), and 137 anti-RNAP- matched patients. A trend toward a higher peak of modified Rodnan Skin Score (RSS) in anti-RNAP+ patients was observed (p:0.07). Interval time between the first symptom of SSc other than Raynaud's phenomenon and the peak of RSS was shorter in anti-RNAP+ cases than in controls (p:0.008; log-rank test). Other differences between the two groups are shown in Figure 1.

Conclusions Analysis of a large, multicenter database and a dedicated case-control study confirm that anti-RNAP is one of the most useful markers available to stratify SSc patients in subsets with peculiar clinical features. These include rapid progression of skin involvement, GAVE, and an increased risk of diagnosis of cancer simultaneous to the onset of SSc. This information should guide monitoring and follow-up in anti-RNAP+ SSc patients.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.